SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Anika Therapeutics, Inc. – ‘S-8’ on 8/4/22

On:  Thursday, 8/4/22, at 5:57pm ET   ·   As of:  8/5/22   ·   Effective:  8/5/22   ·   Accession #:  1171843-22-5377   ·   File #:  333-266550

Previous ‘S-8’:  ‘S-8’ on 11/5/21   ·   Next:  ‘S-8’ on 8/8/23   ·   Latest:  ‘S-8’ on 1/19/24   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/05/22  Anika Therapeutics, Inc.          S-8         8/05/22    4:54K                                    Globenewswire Inc./FA

Registration Statement – Securities for an Employee Benefit Plan   —   Form S-8   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML     33K 
                Employee Benefit Plan                                            
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML      8K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      5K 
 4: EX-FILING FEES  Filing Fee Table                                HTML     11K 


‘S-8’   —   Registration Statement – Securities for an Employee Benefit Plan

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"24.1
"Power of Attorney (included on the signature page of this registration statement)

This is an HTML Document rendered as filed.  [ Alternative Formats ]



As filed with the Securities and Exchange Commission on August 4, 2022

 

Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

Anika Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   04-3145961
(State or other jurisdiction of   (I.R.S. Employer Identification No.
incorporation or organization)    
     
32 Wiggins Avenue    
Bedford, Massachusetts   01730
(Address of principal executive offices)   (Zip code)

 

 

 

2017 Omnibus Incentive Plan

(Full title of the plan)

 

 

 

Cheryl R. Blanchard

President and Chief Executive Officer

Anika Therapeutics, Inc.

32 Wiggins Avenue

Bedford, Massachusetts 01730

(781) 457-9000

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

  With copies to:  
Bella Zaslavsky   David Colleran
K&L Gates LLP   Anika Therapeutics, Inc.
One Lincoln Street   32 Wiggins Avenue
Boston, MA 02111   Bedford, MA 01730
(617) 951-9054   (781) 457-9261

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 C: 
 

 

STATEMENT OF INCORPORATION BY REFERENCE

 

This Registration Statement on Form S-8 relating to the 2017 Omnibus Incentive Plan (the “Plan”) of the registrant is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of the Registration Statements on Form S-8 previously filed by the registrant with the Securities and Exchange Commission on July 7, 2017 (File No. 333-219190), June 21, 2019 (File No. 333-232254), June 19, 2020 (File No. 333-239304), and August 6, 2021 (File No. 333-258529). The Plan was amended effective as of June 8, 2022 solely to authorize an additional 250,000 shares of Anika Therapeutics, Inc. common stock for issuance under the Plan.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

Exhibit Number   Description
     
3.1   Certificate of Incorporation of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 6, 2018)
3.2   Bylaws of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on June 6, 2018)
5.1   Opinion of K&L Gates LLP
23.1   Consent of Deloitte & Touche LLP
23.2   Consent of K&L Gates LLP (included in Exhibit 5.1)
24.1   Power of Attorney (included on the signature page of this registration statement)
99.1   Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended on June 18, 2019, June 16, 2020, June 16, 2021, and June 8, 2022) (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed on June 10, 2022)
107   Filing Fee Table

 

 

 

 

 C: 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedford, Commonwealth of Massachusetts, as of August 4, 2022.

 

  ANIKA THERAPEUTICS, INC.
 

/s/ Cheryl R. Blanchard

  Cheryl R. Blanchard
  President and Chief Executive Officer

 

POWER OF ATTORNEY AND SIGNATURES

 

KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Cheryl R. Blanchard and David Colleran, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments and any registration statement for the same offering that is to be effective under Rule 462(b) of the Securities Act of 1933 to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

         
/s/ Cheryl R. Blanchard   Chief Executive Officer, President and Director   August 4, 2022

Cheryl R. Blanchard

 

(Principal Executive Officer) 

 
         
/s/ Michael L. Levitz   Chief Financial Officer and Treasurer   August 4, 2022
Michael L. Levitz   (Principal Financial and Accounting Officer)    
         
/s/ Jeffery S. Thompson  

Director and Chair of the Board of Directors

  August 4, 2022

Jeffery S. Thompson

   
         
/s/ Sheryl L. Conley   Director   August 4, 2022
Sheryl L. Conley        
         

/s/ John B. Henneman III

  Director   August 4, 2022

John B. Henneman III

   
         
/s/ Glenn R. Larsen   Director   August 4, 2022
Glenn R. Larsen        
         
/s/ Stephen O. Richard   Director   August 4, 2022
Stephen O. Richard        
         

/s/ Susan L.N. Vogt

  Director   August 4, 2022
Susan L.N. Vogt        

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-8’ Filing    Date    Other Filings
Filed as of / Effective on:8/5/22
Filed on:8/4/2210-Q
6/10/224,  8-K
6/8/224,  8-K,  DEF 14A
8/6/2110-Q,  S-8
6/19/20S-8
6/21/19S-8
6/6/188-K
7/7/17S-8
 List all Filings 


2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/22/21  Anika Therapeutics, Inc.          8-K:5,9     6/16/21   12:455K                                   Globenewswire Inc./FA
 6/06/18  Anika Therapeutics, Inc.          8-K:5,8,9   5/31/18    4:323K                                   Globenewswire Inc./FA
Top
Filing Submission 0001171843-22-005377   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 5:25:50.1am ET